Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| VSTM | Verastem, Inc. | 2026-10-15 14:21:22 | 9.29 | 1.58 | 20.49 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VSTM | 0001526119 | Verastem, Inc. | US92337C2035 | 549300IY0EFBIU8NQC81 | 273269467 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | MA | 117 KENDRICK STREET | NEEDHAM | MA | 02494 | UNITED STATES | US | (781) 292-4200 | 117 KENDRICK STREET, NEEDHAM, MA, 02494 | 117 KENDRICK STREET, NEEDHAM, MA, 02494 | — | Pharmaceutical Industry | 2010 | Brian Stuglik | 100 | https://verastem.com | 253,804,995 | 90,482,000 | 90,563,441 | Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index. | 2026-10-09 03:09:30 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 253,804,995 | 174,176,668 | 218.7371 | 87,835,106 | 36,348,401 | 70.5976 |
| 2024 | 79,628,327 | -107,061,182 | -57.3472 | 51,486,705 | 26,191,210 | 103.541 |
| 2023 | 186,689,509 | -29,242,555 | -13.5425 | 25,295,495 | -175,382,484 | -87.395 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Michael Kauffman | President | 2025 | 30,000 | — | 62,331 | 0 | 105,000 | 272,993 |
| Matthew Ros | Chief Operating Officer | 2025 | 455,154 | — | 585,330 | 196,425 | 388,254 | 1,625,163 |
| Daniel Paterson | Chief Executive Officer, President | 2025 | 674,000 | — | 1,161,661 | 489,324 | 24,990 | 2,349,975 |
| Daniel Calkins | Chief Financial Officer | 2025 | 350,000 | — | 450,721 | 151,200 | 24,950 | 976,871 |
| Daniel Calkins | Chief Financial Officer | 2024 | 325,000 | — | 254,079 | 124,000 | 22,690 | 741,010 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 102 |
| 2024 | 78 |
| 2023 | 73 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 30,914,000 | 10,000,000 | — |
| Cost Of Revenue | — | — | — |
| Gross Profit | 30,914,000 | 10,000,000 | 0 |
| Research And Development Expenses | 114,599,000 | 81,334,000 | 61,356,000 |
| General And Administrative Expenses | 81,146,000 | 43,622,000 | 30,728,000 |
| Operating Expenses | 201,043,000 | 124,956,000 | 92,084,000 |
| Operating Income | -170,129,000 | -114,956,000 | -92,084,000 |
| Net Income | -209,471,000 | -130,637,000 | -87,367,000 |
| Earnings Per Share Basic | -3.02 | -3.66 | -3.96 |
| Earnings Per Share Diluted | -3.02 | -3.66 | -3.93 |
| Weighted Average Shares Outstanding Basic | 69,309,000 | 35,713,000 | 22,054,000 |
| Weighted Average Shares Outstanding Diluted | 69,309,000 | 35,713,000 | 22,054,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 204,990,000 | 88,818,000 | 77,909,000 |
| Marketable Securities Current | — | — | 59,220,000 |
| Accounts Receivable | 8,813,000 | — | — |
| Inventories | 1,833,000 | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 7,577,000 | 5,943,000 | 6,553,000 |
| Total Assets Current | 223,413,000 | 94,961,000 | 143,682,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | — | 32,000 | 37,000 |
| Other Assets Non Current | 6,112,000 | 4,899,000 | 4,587,000 |
| Total Assets Non Current | 23,029,000 | 6,577,000 | 6,036,000 |
| Total Assets | 246,442,000 | 101,538,000 | 149,718,000 |
| Accounts Payable | 12,448,000 | 4,026,000 | 7,184,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | 15,000,000 | — |
| Other Liabilities Current | 53,981,000 | 25,952,000 | 17,928,000 |
| Total Liabilities Current | 72,268,000 | 30,973,000 | 26,380,000 |
| Long Term Debt | — | 40,724,000 | 40,086,000 |
| Other Liabilities Non Current | 0 | 0 | 0 |
| Total Liabilities Non Current | 116,977,000 | 99,458,000 | 44,805,000 |
| Total Liabilities | 189,245,000 | 130,431,000 | 71,185,000 |
| Common Stock | 8,000 | 4,000 | 3,000 |
| Retained Earnings | -1,164,998,000 | -955,527,000 | -824,890,000 |
| Accumulated Other Comprehensive Income | 5,229,000 | — | 13,000 |
| Total Shareholders Equity | 57,197,000 | -28,893,000 | 57,374,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 30,000 | 26,000 | 62,000 |
| Share Based Compensation Expense | 9,404,000 | 7,342,000 | 5,860,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 8,813,000 | — | -31,000 |
| Change In Inventories | 1,833,000 | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | 2,605,000 | 596,000 | 5,826,000 |
| Change In Accounts Payable | 8,422,000 | -3,158,000 | 2,283,000 |
| Change In Other Liabilities | 30,833,000 | 7,999,000 | 2,938,000 |
| Cash From Operating Activities | -137,509,000 | -104,771,000 | -86,460,000 |
| Purchases Of Marketable Securities | — | — | 96,447,000 |
| Sales Of Marketable Securities | — | 60,000,000 | 52,000,000 |
| Acquisition Of Property Plant And Equipment | — | 28,000 | — |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -9,624,000 | 59,972,000 | -44,447,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 196,976,000 | 14,221,000 | 91,420,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | 42,579,000 | — | 300,000 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 263,305,000 | 54,782,000 | 134,194,000 |
| Change In Cash | 116,172,000 | 9,983,000 | 3,287,000 |
| Cash At End Of Period | 204,990,000 | 88,818,000 | 77,909,000 |
| Income Taxes Paid | 185,000 | — | — |
| Interest Paid | 6,364,000 | 3,774,000 | 3,361,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -3.02 | -3.66 | -3.96 |
| Price To Earnings Ratio | -2.5563 | -1.4126 | -2.0556 |
| Earnings Growth Rate | -17.4863 | -7.5758 | 942.1053 |
| Price Earnings To Growth Ratio | 0.1462 | 0.1865 | -0.0022 |
| Book Value Per Share | 0.8252 | -0.809 | 3.5609 |
| Price To Book Ratio | 9.3548 | -6.3903 | 2.2859 |
| Ebitda | -208,118,000 | -126,049,000 | -83,166,000 |
| Enterprise Value | — | 151,542,210 | 141,696,560 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | -1.9286 | 0.6987 |
| Capital Expenditures | — | 21,000 | 7,000 |
| Free Cash Flow | — | -104,792,000 | -86,467,000 |
| Return On Equity | -3.6623 | 4.5214 | -1.5228 |
| One Year Beta | 1.3018 | 1.5575 | 2.4035 |
| Three Year Beta | 1.6092 | 1.7297 | 1.6923 |
| Five Year Beta | 1.5694 | 1.504 | 1.4823 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Calkins Daniel | Chief Financial Officer | 2026-10-01 | 2,566 | D | 123,781 |
| Paterson Dan | Director, President and CEO | 2026-10-01 | 44,121 | D | 652,712 |
| Calkins Daniel | Chief Financial Officer | 2026-09-30 | 8,333 | D | 126,347 |
| Paterson Dan | Director, President and CEO | 2026-09-30 | 106,893 | D | 696,833 |
| Calkins Daniel | Chief Financial Officer | 2026-09-21 | 55 | D | 118,014 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Essential Partners LLC | 2026-09-30 | 3,969 | 493 | 8.0507 |
| Hennion & Walsh Asset Management, Inc. | 2026-09-30 | 5,633,615 | 699,828 | 8.05 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 2026-09-30 | 160,130 | 19,745 | 8.1099 |
| True Wealth Design, LLC | 2026-09-30 | 5,716 | 710 | 8.0507 |
| CoreCap Advisors, LLC | 2026-09-30 | 330 | 41 | 8.0488 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Pacer Funds Trust | 2026-07-31 | Pacer WealthShield ETF | PWS | 1,573 | 9,123.4 | 0.0379 |
| ETFis Series Trust I | 2026-07-31 | Virtus Biotech ETF | BBP | 331,013 | 1,919,875.4 | 1.9482 |
| VICTORY PORTFOLIOS III | 2026-07-31 | Victory Extended Market Index Fund | USMIX | 9,462 | 54,879.6 | 0.0068 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2026-07-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 81,901 | 475,025.8 | 0.0172 |
| Global X Funds | 2026-07-31 | Global X Russell 2000 ETF | RSSL | 37,988 | 220,330.4 | 0.0148 |